[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"atopic-dermatitis-ad\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:atopic-dermatitis-ad":30},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,33,0,25,[9,54,82,104,126,160,185,210,232,257,281,305,336,367,388,410,444,465,489,513,533,557,584,604,627],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100645171","phase-2-the-safety-and-efficacy-of-upadacitinib-in-refractory-autoimmune-related-cholangitis-and-atopic-dermatitis-with-moderate-to-severe-itching-100645171",false,"NCT07678645","The Safety and Efficacy of Upadacitinib in Refractory Autoimmune Related Cholangitis and Atopic Dermatitis With Moderate to Severe Itching","Evaluation of the Safety and Efficacy of Upadacitinib in the Treatment of Atopic Dermatitis With Moderate to Severe Itching and Refractory Autoimmune Related Cholangitis: a Single Arm, Exploratory Clinical Study","Inclusion Criteria\n\nPatients must meet all of the following criteria to be eligible for enrollment:\n\n1. Aged ≥18 and ≤70 years, of either sex.\n2. Criteria for Atopic Dermatitis (AD)\n\n   Diagnosis of AD according to the Chinese diagnostic criteria for adult AD, defined as meeting the primary criterion (a) plus either criterion (b) or (c) below:\n   1. Presence of symmetrical eczema with a disease duration of more than 6 months.\n   2. Personal and\u002For first-degree family history of atopic diseases (e.g., eczema, allergic rhinitis, asthma, allergic conjunctivitis, etc.).\n   3. At least one of the following laboratory findings: elevated serum total immunoglobulin E (IgE), elevated peripheral blood eosinophil count, or positive allergen-specific IgE.\n\n   Presence of moderate-to-severe pruritus, defined as a Visual Analogue Scale (VAS) score ≥4.\n3. Criteria for Primary Biliary Cholangitis (PBC)\n\n   Diagnosis of PBC according to practice guideline criteria, defined as meeting at least two of the following three criteria:\n   1. Biochemical evidence of cholestasis, primarily elevated alkaline phosphatase (ALP) and\u002For gamma-glutamyl transferase (GGT).\n   2. Positivity for anti-mitochondrial antibody (AMA) or AMA-M2, or positivity for other disease-specific autoantibodies (anti-gp210 or anti-sp100 antibodies).\n   3. Histological evidence of non-suppurative destructive cholangitis and small bile duct destruction.\n\n   Patients must have received a standard regimen of ursodeoxycholic acid (UDCA) for ≥12 months (at a dose of no less than 13-15 mg\u002Fkg\u002Fday) in combination with at least two subsequent-line therapies (including Farnesoid X receptor agonists, peroxisome proliferator-activated receptor agonists, budesonide, or other immunosuppressants) for ≥3 months.\n\n   At screening, ALP ≥1.5 × upper limit of normal (ULN) or GGT ≥5 × ULN.\n4. Criteria for Primary Sclerosing Cholangitis (PSC)\n\nFor large-duct PSC, diagnosis must meet the following criteria:\n\n1. Biliary imaging showing characteristic multifocal, short-segmental, or annular strictures involving both intra- and extrahepatic bile ducts.\n2. At least one of the following clinical manifestations: biochemical evidence of cholestasis (primarily elevated ALP and\u002For GGT); clinical or histological evidence of coexisting inflammatory bowel disease (IBD); or liver histology showing periductal inflammation with fibrosis (i.e., periductal \"onion-skin\" appearance).\n3. Exclusion of secondary sclerosing cholangitis due to other etiologies.\n\nFor small-duct PSC, diagnosis must meet the following criteria:\n\n1. Biochemical evidence of cholestasis with no significant abnormalities on recent biliary imaging.\n2. Liver histology showing typical PSC changes as described above (periductal inflammation with fibrosis \u002F \"onion-skin\" appearance).\n3. Exclusion of other causes of cholestasis. Patients must have received a standard regimen of UDCA for ≥3 months (at a dose of no less than 13-15 mg\u002Fkg\u002Fday). At screening, ALP ≥1.5 × ULN or GGT ≥5 × ULN.\n\nExclusion Criteria\n\nPatients who meet any of the following criteria will be excluded from enrollment:\n\n1. Known concurrent or history of other hepatobiliary diseases, including but not limited to: active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection; complete biliary obstruction; acute cholecystitis or symptomatic cholelithiasis; suspected or confirmed hepatocellular carcinoma (HCC) or cholangiocarcinoma.\n2. Child-Pugh Class C cirrhosis; evidence of end-stage liver disease, including: history of liver transplantation or being on the liver transplant waiting list; Model for End-Stage Liver Disease (MELD) score \\>20; severe portal hypertension complications (including severe gastric or esophageal varices, refractory or diuretic-resistant ascites, history of variceal bleeding); or other serious cirrhosis-related complications (spontaneous bacterial peritonitis, hepatic encephalopathy, hepatorenal syndrome, hepatopulmonary syndrome).\n3. Total bilirubin \\>10 × upper limit of normal (ULN).\n4. Serum creatinine ≥1.5 × ULN and creatinine clearance \\\u003C60 mL\u002Fmin.\n5. Platelet count \\\u003C50 × 10⁹\u002FL.\n6. International normalized ratio (INR) \\>1.5.\n7. Serum albumin \\\u003C3.0 g\u002FdL.\n8. Use of moderate or strong inhibitors or inducers of cytochrome P450 3A4 (CYP3A4) within 14 days prior to the first dose of study drug or planned use throughout the study period.\n9. Presence of diseases that may cause non-hepatic elevation of ALP (e.g., Paget's disease of bone) or any condition with an anticipated life expectancy of less than 2 years.\n10. Known drug abuse or alcohol abuse within 6 months prior to the first dose of study drug, defined as weekly alcohol consumption exceeding 14 standard drinks (1 standard drink equivalent to 360 mL beer, 45 mL of 40% distilled spirits, or 150 mL wine).\n11. Unstable concomitant diseases or use of concomitant medications that cannot be maintained on a stable regimen throughout the clinical study period.\n12. Pregnant women, women planning to become pregnant, breastfeeding women, or fertile patients (male or female) who are unwilling to use at least one effective method of contraception from the time of signing informed consent until 30 days after the last dose of study drug.\n13. Participation in any other interventional clinical trial and receipt of any investigational product within 3 months prior to the first dose of study drug.\n14. Positive results for human immunodeficiency virus antibodies (HIV Ab) or Treponema pallidum antibodies (TP Ab).\n15. Any other condition that, in the investigator's judgment, would preclude the patient's participation in this study.","ALL","18 Years","70 Years",{"count":21,"type":22},44,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","Cholestatic liver diseases are characterized by jaundice, pruritus, and elevated levels of alkaline phosphatase (ALP) and gamma-glutamyl transferase (GGT). Primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) represent the major autoimmune-driven entities within this category. Without effective intervention, these conditions may progress to liver failure and even death. Ursodeoxycholic acid (UDCA), the first-line therapy for PBC, has been shown to improve prognosis; however, 20%-40% of patients exhibit an inadequate biochemical response. For PSC, no clearly effective pharmacologic agent is currently available. In refractory patients, pruritus often progressively worsens, severely impairing quality of life and treatment adherence, underscoring an urgent need for novel therapeutic approaches that simultaneously address disease control and itch relief.\n\nAutoimmune-associated cholangitis frequently coexists with atopic dermatitis, and in a subset of patients, pruritus may be compounded by dermatologic factors. The pruritus of atopic dermatitis involves the JAK-STAT signaling pathway, which not only serves as a convergent node for pruritic signals but also constitutes a key downstream hub in the immune dysregulation characteristic of cholangitis. Inhibition of this pathway is therefore hypothesized to alleviate pruritus and modulate aberrant immune responses. Case reports have suggested that upadacitinib, a selective JAK inhibitor, may improve biochemical parameters in refractory PBC and exhibit potential anti-fibrotic effects.\n\nTo this end, investigators plan to conduct an exploratory clinical study to systematically evaluate the safety and efficacy of upadacitinib in patients with atopic dermatitis complicated by moderate-to-severe pruritus and refractory autoimmune-associated cholangitis.",[28,29,30],"Primary Biliary Cholangitis (PBC)","Primary Sclerosing Cholangitis (PSC)","Atopic Dermatitis (AD)",[28,29,30,32,33,34,35,36,37,38,39,40],"pruritus","upadacitinib","cholangitis","bile duct diseases","biliary tract diseases","Digestive System Diseases","Cirrhosis, Biliary","Cholangitis, Biliary","Cholangitis, Sclerosing","NOT_YET_RECRUITING","2026-06-30",{"date":44,"type":45},"2026-07-01","ACTUAL",{"date":47,"type":22},"2026-06-01",{"date":49,"type":22},"2028-05-31",{"name":51,"class":52},"RenJi Hospital","OTHER",1,{"id":55,"slug":56,"hasResults":12,"nctId":57,"briefTitle":58,"officialTitle":58,"acronym":59,"eligibilityCriteria":60,"healthyVolunteers":12,"sex":17,"minAge":61,"maxAge":4,"enrollmentInfo":62,"targetDuration":64,"studyType":65,"phases":4,"briefSummary":66,"conditions":67,"keywords":69,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":53},"100642524","global-healthcare-study-on-atopic-dermatitis-100642524","NCT07659756","Global Healthcare Study on Atopic Dermatitis","GHSAD","Inclusion Criteria:\n\n* Signed General Consent Form, or equivalent document\n* Confirmed diagnosis of Atopic Dermatitis\n\nExclusion Criteria:\n\n* Inability to provide informed consent.\n* Datasets with ambiguous or unclear diagnosis.","14 Years",{"count":63,"type":22},9600,"5 Years","OBSERVATIONAL","The Global Healthcare Study on Atopic Dermatitis (GHSAD) is an international, multicenter observational study hosted by the University of Zurich (UZH) investigating healthcare access, treatment patterns, disease severity, and quality of life in patients with atopic dermatitis. The study collects standardized clinical data from routine medical records to identify disparities in healthcare delivery and outcomes across different healthcare systems.",[30,68],"Atopic Dermatitis (Eczema)",[70,59,71],"Dermastudy","GHRSD","RECRUITING","2026-06-15",{"date":75,"type":45},"2026-06-22",{"date":77,"type":45},"2025-01-01",{"date":79,"type":22},"2029-12-31",{"name":81,"class":52},"Julia Tatjana Maul",{"id":83,"slug":84,"hasResults":12,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":4,"eligibilityCriteria":88,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":89,"targetDuration":91,"studyType":65,"phases":4,"briefSummary":92,"conditions":93,"keywords":4,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":53},"100634836","a-study-of-stapokibart-injection-in-patients-with-atopic-dermatitis-ad-100634836","NCT07544862","A Study of Stapokibart Injection in Patients With Atopic Dermatitis (AD)","A Prospective Study of Stapokibart Injection in Patients With Moderate-to-Severe Atopic Dermatitis (AD)","Inclusion Criteria:\n\n* Trial participants aged 18 years or older at baseline, with no restrictions on gender.\n* Physician decision to treat trial participants with Stapokibart Injection for AD (according to the China-specific prescribing information) made prior to and independently of the participant's participation in the study.\n\nExclusion Criteria:\n\n* Known history of allergic reaction to Stapokibart Injection.\n* Trial participants currently or plan participating in any interventional clinical trial.\n* Trial participants with hematologic malignancies.\n* Women with pregnant.\n* Any condition that, in the opinion of the investigator, may interfere with trial participants' ability to participate in the study.",{"count":90,"type":22},1000,"52 Weeks","This study is an open label, prospective study to evaluate the safety and efficacy of Stapokibart Injection in patients with AD.",[30],"2026-06-08",{"date":96,"type":45},"2026-06-10",{"date":98,"type":45},"2026-06-02",{"date":100,"type":22},"2028-02",{"name":102,"class":103},"Chengdu Kangnuoxing Biopharma,Inc.","INDUSTRY",{"id":105,"slug":106,"hasResults":12,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":4,"eligibilityCriteria":110,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":111,"enrollmentInfo":112,"targetDuration":4,"studyType":23,"phases":114,"briefSummary":115,"conditions":116,"keywords":4,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":125},"100615883","phase-2-study-of-env-294-in-adults-with-moderate-to-severe-atopic-dermatitis-100615883","NCT07298395","Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis","A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 12-Week Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ENV-294 in Adult Participants With Moderate-to-Severe Atopic Dermatitis","Inclusion Criteria:\n\n* Have chronic atopic dermatitis that was diagnosed at least 12 months prior to the first study visit\n* Have moderate-to-severe AD at screening and baseline as defined by the following criteria:\n\n  * A vIGA score of 3 (moderate) or 4 (severe)\n  * EASI score of ≥16\n  * BSA ≥10%\n  * PP-NRS score of ≥4\n* Have had either a poor response or intolerance to topical treatments for atopic dermatitis (such as corticosteroids) within the past 6 months\n* Use a bland moisturizer at least daily\n\nExclusion Criteria:\n\n* Current or recurrent medical conditions that could affect the study drug or study assessments\n* Any illness that could impact participant safety or active infections\n* Ongoing skin condition or large tattoos that would interfere with clinical assessment\n* Clinically significant skin infection requiring treatment\n* Clinically significant abnormal laboratory assessments at screening","75 Years",{"count":113,"type":22},60,[25],"The goal of this clinical trial is to learn about the safety and effectiveness of ENV-294 in adults with moderate to severe atopic dermatitis.\n\nThe main questions it will answer are:\n\n* Is there an impact on the severity and area of atopic dermatitis when participants take ENV-294\n* What medical problems do participants have when taking ENV-294\n\nParticipants will:\n\n* Take drug ENV-294 or a placebo once every day for 12 weeks\n* Visit the clinic every 2 to 4 weeks for checkups and tests\n* Keep a diary of their symptoms and when they took their study drug\n* Return to the clinic for the final study visit at approximately week 16",[30],{"date":118,"type":45},"2026-06-04",{"date":120,"type":45},"2025-12-22",{"date":122,"type":22},"2026-12",{"name":124,"class":103},"Enveda Therapeutics",23,{"id":127,"slug":128,"hasResults":12,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":4,"eligibilityCriteria":132,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":111,"enrollmentInfo":133,"targetDuration":4,"studyType":23,"phases":135,"briefSummary":137,"conditions":138,"keywords":144,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":153,"completionDateStruct":155,"leadSponsor":157,"locationsCount":159},"100627972","phase-1-study-of-s-4321-in-participants-with-an-autoimmune-or-immune-mediated-disease-100627972","NCT07455578","Study of S-4321 in Participants With an Autoimmune or Immune-mediated Disease","Phase 1b, Open-Label, Exploratory Biomarker Basket Study of S-4321 in Participants With an Autoimmune or Immune-Mediated Disease","All Participants Major Inclusion Criteria:\n\n1. Adult males and females, 18 to 75 years of age (inclusive)\n2. Body mass index (BMI) ≥18.0 and \\\u003C40.0 kg\u002Fm2 with a minimum body weight of 45 kg\n3. Use of adequate contraception for both males and females. Female volunteers must be of nonchildbearing potential or if of childbearing potential, must have a negative pregnancy test.\n\nAll Participants Major Exclusion Criteria:\n\n1. Have received a PD-1 agonist, immune checkpoint agonist, immune checkpoint inhibitor, anti-CD19 or anti-CD20 agents, cell therapy, B cell modulating agents, alkylating agents, or any other immune cell depleting therapy.\n2. Have received azathioprine, cyclosporine, mycophenolate mofetil, or tacrolimus within 4 weeks\n3. Unable or unwilling to discontinue a prohibited medication\n4. Presence of clinically relevant immunosuppression\n5. Current infection or history of severe infection\n6. Any history of malignant disease, with some exceptions\n\nMajor inclusion\u002Fexclusion for each autoimmune or immune-mediated disease:\n\nFor RA:\n\n1. Confirmed diagnosis of moderate to severe active RA by the American College of Rheumatology (ACR) 2010\u002FEuropean League Against Rheumatism (EULAR) criteria for at least 3 months prior to the Screening 1 visit, and:\n\n   1. ≥6 swollen joint count based on 66 joint count\n   2. ≥6 tender joint count based on 68 joint count\n   3. Seropositive for RF and\u002For ACPA\n   4. Elevated hsCRP ≥1.2 times greater than the ULN\n   5. Does not have Class IV RA according to ACR revised criteria\n2. Inadequate response to, or loss of response, or intolerance to:\n\n   1. \\>1 conventional synthetic DMARD after 3 months of therapy OR\n   2. \\>1 biologic DMARD\u002Ftargeted synthetic DMARD after 3 months of therapy\n   3. Has not failed 3 or more bDMARDs and\u002For tsDMARDs\n\nFor PsA:\n\n1. Confirmed diagnosis of adult-onset PsA classified by the Classification Criteria for Psoriatic Arthritis (CASPAR) for at least 3 months prior to the Screening 1 visit, with all of the following:\n\n   1. Active PsO defined by at least 1 psoriasis lesion\n   2. Active disease defined by \\>3 swollen joints and \\>3 tender joints using the 76\u002F78 swollen and tender joint count\n2. Received standard doses of NSAIDs for \\>4 weeks or csDMARDs for \\>3 months and has been on a stable dose for \\>8 weeks, or participant has intolerance to NSAIDs or DMARDs\n3. Participants may be TNF inhibitor therapy naïve or may have received 1 prior TNF inhibitor\n4. Has not had inadequate response or intolerance to 2 or more bDMARDs or csDMARDs\n\nFor PsO:\n\n1. Confirmed diagnosis of moderate to severe plaque PsO for at least 6 months, with all of the following:\n\n   1. Psoriasis Area and Severity Index (PASI) \\>12 points\n   2. Static Physician's Global Assessment (sPGA) \\>3 points\n   3. Body surface area (BSA) of PsO involvement \\>10%\n2. Cannot have a clinically significant flare within 12 weeks\n3. Does not have history of erythrodermic psoriasis, generalized or localized pustular psoriasis, predominantly guttate psoriasis, or medication-induced or medication-exacerbated psoriasis\n4. Has not had inadequate response to more than 2 prior bDMARDs\n\nFor CLE (with or without systemic manifestations):\n\n1. Histologically confirmed diagnosis of CLE with or without systemic manifestations for at least 6 months\n2. Has active skin manifestations as measured by CLASI-A \\>10 or CLASI-A \\>8, if there is no alopecia or mucous membrane lesions\n3. Participant must have an active CLE lesion despite an adequate trial of antimalarial treatment for at least 6 months.\n4. Cannot have active lupus nephritis or moderate-to-severe or chronic kidney disease with eGFR \\\u003C45 mL\u002Fmin\u002F1.73m2\n5. Cannot have active neuropsychiatric SLE\n\nFor AD:\n\n1. Confirmed diagnosis of AD as defined by the American Academy of Dermatology: Guidelines of Care for the Management of Atopic Dermatitis for at least 12 months\n\n   1. Eczema Area and Severity Index (EASI) \\>16\n   2. Validated Investigator Global Assessment (vIGA-AD) \\>3\n   3. BSA of AD involvement \\>10%\n   4. PP-NRS) \\>4 (average of daily scores) during the 7 days prior to dosing\n2. Inadequate response to existing topical medications within 6 months or has a history of intolerance to topical therapy as defined by at least 1 of the following:\n\n   1. Inability to achieve good disease control after use TCS for at least 4 weeks\n   2. Documented history of clinically significant AEs with the use of TCS\n   3. Failed systemic therapies intended to treat AD within 6 months\n\nAdditional inclusion\u002Fexclusion criteria will apply.",{"count":134,"type":22},24,[136],"PHASE1","This is a multi-center, open-label Ph 1b basket study to assess safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity, biomarker response, and preliminary efficacy of multiple doses of S-4321 in adults with autoimmune or immune-mediated disease including rheumatoid arthritis (RA), psoriatic arthritis (PsA), psoriasis (PsO), cutaneous lupus erythematosus (CLE) with or without systemic manifestations, or atopic dermatitis (AD).",[139,140,141,142,143,30],"Autoimmune Diseases","Rheumatoid Arthritis (RA)","Psoriatic Arthritis (PsA)","Psoriasis (PsO)","Cutaneous Lupus Erythematosus (CLE)",[145,146,147,148,149,30,142,141,143,150],"Autoimmune","Immune-mediated","S-4321","Seismic Therapeutic","Rheumatoid Arthritis","Cutaneous Lupus","2026-05-28",{"date":47,"type":45},{"date":154,"type":22},"2026-06",{"date":156,"type":22},"2027-09",{"name":158,"class":103},"Seismic Therapeutic AU Pty Ltd",2,{"id":161,"slug":162,"hasResults":12,"nctId":163,"briefTitle":164,"officialTitle":165,"acronym":166,"eligibilityCriteria":167,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":111,"enrollmentInfo":168,"targetDuration":4,"studyType":23,"phases":170,"briefSummary":171,"conditions":172,"keywords":173,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":176,"startDateStruct":178,"completionDateStruct":180,"leadSponsor":182,"locationsCount":184},"100601053","phase-2-a-study-evaluating-bfb759-in-moderate-to-severe-atopic-dermatitis-100601053","NCT07105488","A Study Evaluating BFB759 in Moderate to Severe Atopic Dermatitis","A Phase 2, Parallel-arm, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of BFB759 in Patients With Atopic Dermatitis (COMPASS 2-AD)","COMPASS 2-AD","Inclusion Criteria:\n\n* Are adults (18-75) with a diagnosis of atopic dermatitis for at least one year.\n* Have moderate to severe disease not adequately controlled by topical treatments.\n* Are willing to follow study instructions, attend regular visits, and avoid certain other medications during the study.\n\nExclusion Criteria:\n\n* Have certain infections or other immune conditions.\n* Recently used medications that could interfere with the study.\n* Are pregnant or breastfeeding.",{"count":169,"type":22},225,[25],"This is a double-blind, placebo-controlled study where subjects are participating for approximately 36 to 40 weeks. The study compares how well BFB759 works and how safe it is compared with a placebo.",[30],[174,175],"Atopic Dermatitis","Eczema",{"date":177,"type":45},"2026-05-29",{"date":179,"type":45},"2025-07-15",{"date":181,"type":22},"2027-03-31",{"name":183,"class":103},"Bluefin Biomedicine, Inc.",88,{"id":186,"slug":187,"hasResults":12,"nctId":188,"briefTitle":189,"officialTitle":190,"acronym":4,"eligibilityCriteria":191,"healthyVolunteers":192,"sex":17,"minAge":18,"maxAge":193,"enrollmentInfo":194,"targetDuration":4,"studyType":23,"phases":196,"briefSummary":197,"conditions":198,"keywords":199,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":201,"lastUpdatePostDateStruct":202,"startDateStruct":204,"completionDateStruct":206,"leadSponsor":208,"locationsCount":53},"100627820","phase-1-ph-1a1b-single-ascending-dose-and-multiple-ascending-dose-study-of-arq-234-100627820","NCT07453602","Ph 1a\u002F1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234","A Phase 1a\u002F1b, Double-Blind, Randomized, Placebo-Controlled, Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234 in Healthy Volunteers and Subjects With Moderate to Severe Atopic Dermatitis.","Inclusion Criteria (All Participants):\n\n* Able and willing to provide written informed consent.\n* Adults 18-65 years (inclusive) at consent.\n* Generally healthy at screening\u002Fbaseline (no clinically significant findings on medical history, exam, vitals, ECG, or safety labs, per investigator).\n* Contraception requirements: Females of childbearing potential: negative pregnancy tests at screening and baseline and agree to use highly effective contraception (plus barrier method) during the study and for 4 months after last dose. Males if sexually active with a pregnant partner or a female of childbearing potential, agree to condom use during the study and for 4 months after last dose.\n* Body weight by study part: Part A (SAD) \\& Part B (MAD): 50-100 kg (inclusive), Part C (POC): 50-125 kg (inclusive)\n\nInclusion Criteria for atopic dermatitis (AD) Participants (Parts A Cohorts 6-7, Part B, Part C):\n\n* Diagnosis of moderate-to-severe atopic dermatitis for ≥ 6 months prior to screening.\n* Meets minimum disease severity at baseline: Part A Cohorts 6-7: BSA ≥7%, vIGA-AD 3-4, EASI ≥10 at Baseline, Parts B and C: BSA ≥10%, vIGA-AD 3-4, EASI ≥16 at Baseline.\n* Inadequate response, intolerance, or medical inappropriateness of topical AD therapies (and\u002For prior systemic AD therapy failure within the last year may qualify as inadequate response).\n\nExclusion Criteria (All Participants):\n\n* Any clinically significant medical or psychiatric condition that could increase risk, interfere with participation, or confound results (per investigator).\n* Significant renal impairment or clinically significant hepatic impairment (per protocol\u002Fpart-specific definitions).\n* Clinically significant cytopenias or clinically significant abnormal liver tests at screening (per protocol).\n* History of anaphylaxis\u002Fserious hypersensitivity (including significant hypersensitivity to local anesthetics).\n* History of attempted suicide or significant current risk, per investigator).\n* Chronic or significant infection history or positive screening tests for hepatitis B, hepatitis C, HIV, or tuberculosis (including positive QuantiFERON or history of active\u002Flatent TB).\n* Known\u002Fsuspected immunosuppression or history of invasive opportunistic infections or unusually frequent\u002Frecurrent\u002Fprolonged infections (per investigator).\n* Recent herpes zoster that poses risk or may affect interpretation (per investigator).\n* Malignancy within 5 years prior to screening\n* Positive urine drug screen at screening (Part A\u002FPart B only) or drug\u002Falcohol abuse within 12 months, or other condition likely to impair compliance (per investigator).\n* Unable to discontinue prohibited medications\u002Ftreatments per protocol.\n* Major surgery within 4 weeks prior to baseline or planned during participation.\n* Participation in another trial or receipt of investigational product within 12 weeks (or 5 half-lives, whichever longer) before baseline.\n* Prior cell-depleting therapy (e.g., rituximab) within 6 months prior to baseline (or until lymphocytes normalize, whichever longer).\n* Blood products within 4 weeks prior to baseline or planned during participation.\n* Live (attenuated) vaccines within 28 days prior to baseline or planned during the study.\n* Pregnant or breastfeeding, or planning pregnancy during the study or within 4 months after last dose.\n* Known\u002Fsuspected allergy to ARQ-234 or its excipients.\n* Unable to communicate\u002Funderstand the local language or otherwise unsuitable per investigator.\n* Family member of study staff or sponsor.\n\nExclusion Criteria for atopic dermatitis (AD) Participants (Parts A Cohorts 6-7, Part B, Part C):\n\n* Skin disease(s) other than AD that would interfere with assessments.\n* Active systemic\u002Flocal infection, including actively infected AD, or infection requiring oral\u002FIV antimicrobials within 14 days before baseline.\n* Phototherapy\u002Ftanning bed use within 4 weeks prior to baseline.\n* Biologic therapy for AD within 3 months or 5 half-lives (whichever longer) prior to baseline.\n* Expected need for rescue therapy for AD within the first 2 weeks after baseline.\n* History of eczema herpeticum within 12 months or ≥2 prior episodes.",true,"65 Years",{"count":195,"type":22},125,[136],"This is a first-in-human, Phase 1, double-blind, randomized, placebo-controlled, dose-escalation study evaluating ARQ-234. The study is designed to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of ARQ-234 in two populations: healthy volunteers and participants with moderate to severe atopic dermatitis (AD). Healthy volunteers will participate in Single Ascending Dose (SAD) Cohorts 1-5. Participants with moderate to severe AD will be enrolled in SAD Cohorts 6-7, Multiple Ascending Dose (MAD) Cohorts, and a Proof-of-Concept (POC) expansion cohort.",[30,175],[200],"ARQ-234","2026-05-20",{"date":203,"type":45},"2026-05-22",{"date":205,"type":45},"2026-03-02",{"date":207,"type":22},"2028-04",{"name":209,"class":103},"Arcutis Biotherapeutics, Inc.",{"id":211,"slug":212,"hasResults":12,"nctId":213,"briefTitle":214,"officialTitle":215,"acronym":4,"eligibilityCriteria":216,"healthyVolunteers":192,"sex":217,"minAge":18,"maxAge":218,"enrollmentInfo":219,"targetDuration":4,"studyType":23,"phases":221,"briefSummary":222,"conditions":223,"keywords":4,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":224,"lastUpdatePostDateStruct":225,"startDateStruct":226,"completionDateStruct":228,"leadSponsor":230,"locationsCount":53},"100624601","phase-1-a-phase-1-clinical-study-comparing-gs101-and-dupixent-after-subcutaneous-injection-100624601","NCT07411755","A Phase 1 Clinical Study Comparing GS101 and Dupixent® After Subcutaneous Injection","A Randomized, Double-blind, Parallel, Single-dose, Phase 1 Clinical Study to Compare the Pharmacokinetics, Safety, Tolerability, and Immunogenicity of GS101 Versus Dupixent® After Subcutaneous Injection","Inclusion Criteria:\n\n* No clinically significant abnormalities detected in physical examination, vital signs, chest X-ray (posteroanterior \\[PA\\] view), 12-lead ECG, or laboratory tests prior to investigational product administration.\n* Body mass index (BMI) between 19 and 26 kg\u002Fm² (inclusive) and body weight between 55 and 85 kg (inclusive).\n* Participants and their partner agree to use medically accepted contraceptive methods from the signing of the informed consent form until three months after dosing of the investigational product. In addition, participants have no plans to donate sperm, and their partner has no plans for pregnancy.\n\nExclusion Criteria:\n\n* History or presence at screening of neurological\u002Fpsychiatric, respiratory, cardiovascular, gastrointestinal, hematologic\u002Flymphatic, endocrine, musculoskeletal, or any other disease judged by the investigator to interfere with study assessments.\n* History of drug or food allergy (≥2 types) or history of specific allergic diseases (e.g., asthma, urticaria, eczematous dermatitis), or known hypersensitivity to monoclonal antibodies targeting the same pathway or to investigational product components.\n* Positive result for any infectious disease screening, including human immunodeficiency virus (HIV) antibody and p24 antigen, hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) IgG antibody, or Treponema pallidum (syphilis) antibody.","MALE","55 Years",{"count":220,"type":22},294,[136],"This is a randomized, double-blind, three-arm, parallel-group study designed to demonstrate the similarity of the pharmacokinetics (PK), safety, and immunogenicity of GS101 injection compared with U.S. commercial Dupixent® and CN commercial Dupixent® in healthy adult participants in China. A total of 294 healthy male adult participants, with 98 participants per treatment group across 3 groups.",[30],"2026-05-18",{"date":201,"type":45},{"date":227,"type":45},"2026-03-05",{"date":229,"type":22},"2026-09",{"name":231,"class":103},"Jiangsu Genscend Biopharmaceutical Co., Ltd",{"id":233,"slug":234,"hasResults":12,"nctId":235,"briefTitle":236,"officialTitle":237,"acronym":238,"eligibilityCriteria":239,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":240,"targetDuration":4,"studyType":23,"phases":242,"briefSummary":243,"conditions":244,"keywords":245,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":248,"lastUpdatePostDateStruct":249,"startDateStruct":251,"completionDateStruct":253,"leadSponsor":255,"locationsCount":159},"100587427","phase-1-the-impact-of-botox-on-neuroimmune-interactions-in-atopic-dermatitis-100587427","NCT06928246","The Impact of Botox on Neuroimmune Interactions in Atopic Dermatitis","Pilot Study on Cellular and Molecular Impact of Neuroimmune Interactions in Atopic Dermatitis","AD","Inclusion Criteria:\n\nPhase 1b:\n\n* Patients 18 years or older at time of consent\n* Mild-to-Moderate AD, defined as:\n* BSA ≤ 10%\n* IGA ≤ 3\n* No past biologic therapy\n* No systemic therapy for 3 months\n* No topical therapy for treatment of AD for 4 weeks\n\nPhase 2:\n\n* Patients 18 years or older at time of consent\n* Mild-to-Moderate AD, defined as:\n* BSA ≤ 10%\n* IGA ≤ 3\n* At least one patch of eczema of at least 5 cm in diameter\n* No past biologic therapy\n* No systemic therapy for 3 months\n* No topical therapy for treatment of AD for 4 weeks\n\nExclusion Criteria:\n\nPhase 1b:\n\n* Age less than 18 years old\n* Pregnant or breastfeeding\n* Has medical comorbidity such as end stage congestive heart failure or coagulopathy that is a relative contradiction to skin biopsy procedure\n* Has had prior exposure to biologic treatments or has had prior treatment with systemic non-biologics (e.g. methotrexate) within 12 weeks\n* Has used topical therapy for treatment of AD within 4 weeks\n\nPhase 2:\n\n* Patients enrolled in Phase 1\n* Age less than 18 years old\n* Pregnant or breastfeeding\n* Has medical comorbidity such as end stage congestive heart failure or coagulopathy that is a relative contradiction to skin biopsy procedure\n* Has had prior exposure to biologic treatments or has had prior treatment with systemic non-biologics (e.g. methotrexate) within 12 weeks\n* Has used topical therapy for treatment of AD within 4 weeks",{"count":241,"type":22},8,[136],"The purpose of this study is to understand cellular and molecular interactions in the skin of participants with mild-to-moderate AD, and how botulinum toxin alters these interactions.",[30],[246,175,247],"Atopic dermatitis","Botox","2026-05-01",{"date":250,"type":45},"2026-05-04",{"date":252,"type":45},"2025-07-17",{"date":254,"type":22},"2027-01",{"name":256,"class":52},"Daniel Kaplan",{"id":258,"slug":259,"hasResults":12,"nctId":260,"briefTitle":261,"officialTitle":261,"acronym":262,"eligibilityCriteria":263,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":264,"targetDuration":4,"studyType":65,"phases":4,"briefSummary":266,"conditions":267,"keywords":268,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":272,"lastUpdatePostDateStruct":273,"startDateStruct":275,"completionDateStruct":277,"leadSponsor":279,"locationsCount":53},"100636667","evaluation-by-confocal-reflectance-microscopy-of-the-skin-structure-of-patients-with-atopic-dermatitis-treated-with-tralokinumab-biotherapy-100636667","NCT07568665","Evaluation by Confocal Reflectance Microscopy of the Skin Structure of Patients With Atopic Dermatitis Treated With Tralokinumab Biotherapy.","ADUTERCoM","Inclusion Criteria:\n\n* Patients aged 18 years and older.\n* Patients with moderate-to-severe Atopic Dermatitis who require systemic treatment with tralokinumab in the investigator's opinion.\n* Patients affiliated with or entitled to a social security scheme.\n* Patients capable of giving informed consent.\n* Patients who have received informed information about the study and have co-signed an informed consent form for participation in the study, along with the investigator.\n\nExclusion Criteria:\n\n* Patients who refuse to participate in the study and legally incapacitated adults\n* Patients with an uncontrolled chronic disease that may require corticosteroid courses\u002Ftreatment.\n* Patients with a severe concomitant disease that, in the investigator's opinion, would negatively affect participation in the study.",{"count":265,"type":22},15,"Atopic dermatitis (AD) is a chronic inflammatory skin disease with pruritus and recurrence of eczematous eruptions. Evaluation of response to treatment are only clinical using Eczema Area Severity Index (EASI), SCOring of Atopic Dermatitis Index (SCORAD) scores, with a risk of intra-observer variations. Tralokinumab is a fully human anti-IL-13 monoclonal antibody that has proven to be effective and well-tolerated for the treatment of patients with moderate-to-severe AD. Reflectance confocal microscopy (RCM) is a noninvasive procedure that allows to evaluate epidermis and papillary dermis at a cellular level. RCM allows skin structural and inflammatory parameters evaluation.\n\nThe aim of this study is to evaluate by RCM skin modifications of AD patients treated with tralokinumab.",[30,68],[269,270,271],"atopic dermatis","Reflectance Confocal Microscopy","tralokinumab","2026-04-28",{"date":274,"type":45},"2026-05-06",{"date":276,"type":45},"2025-11-27",{"date":278,"type":22},"2028-11-01",{"name":280,"class":52},"Hôpitaux Drôme Nord",{"id":282,"slug":283,"hasResults":12,"nctId":284,"briefTitle":285,"officialTitle":286,"acronym":4,"eligibilityCriteria":287,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":111,"enrollmentInfo":288,"targetDuration":4,"studyType":23,"phases":290,"briefSummary":292,"conditions":293,"keywords":294,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":296,"lastUpdatePostDateStruct":297,"startDateStruct":299,"completionDateStruct":301,"leadSponsor":303,"locationsCount":4},"100635266","efficacy-and-safety-of-switching-to-ivarmacitinib-in-patients-with-moderate-to-severe-atopic-dermatitis-with-inadequate-response-to-interleukin-4-receptor-alphail-4r-inhibitors-a-prospective-multicenter-real-world-study-100635266","NCT07550452","Efficacy and Safety of Switching to Ivarmacitinib in Patients With Moderate-to-Severe Atopic Dermatitis With Inadequate Response to Interleukin-4 Receptor Alpha(IL-4Rα) Inhibitors: A Prospective, Multicenter, Real-World Study","Efficacy and Safety of Switching to Ivarmacitinib in Patients With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to IL-4Rα Inhibitors","Inclusion Criteria:\n\n* Aged between 18 and 75 years.\n* Patients diagnosed with moderate-to-severe atopic dermatitis and treated with IL-4Rα inhibitors according to standard regimens for a minimum of 12 weeks.\n* Meeting any of the following disease activity criteria: EASI ≥16, WI-NRS ≥4.\n\nExclusion Criteria:\n\n* Treatment with other JAK inhibitors, including topical formulations, within one week before enrollment.\n* Subjects with clinically significant diseases of the heart, liver, kidney, or other major organ systems.\n* Subject has any of the following abnormalities in clinical laboratory tests at screening, as assessed by the study-specific laboratory and confirmed by a single repeat, if deemed necessary:\n\n  a. Absolute lymphocyte count of \\\u003C0.50 x 10\\^9 \u002FL (\\\u003C500\u002Fmm3);b. Absolute Neutrophil Count (ANC) of \\\u003C1 X 10\\^9\u002FL (\\\u003C1000\u002Fmm3);c. Hemoglobin level \\\u003C 80 g\u002FL.\n* Subject with a prior history of thromboembolic events, including deep vein thromboses (DVT), pulmonary embolism, cerebrovascular accidents and those with known inherited conditions that predispose to hypercoagulability.\n* Presence of an active severe acute or chronic bacterial, fungal, or viral infection requiring systemic therapy.\n* Subjects with active tuberculosis or known active hepatitis B and\u002For hepatitis C infection.\n* Subject has any malignancies or has a history of malignancies with the exception of adequately treated or excised non-metastatic basal cell or squamous cell cancer of the skin, or cervical carcinoma in situ.\n* Pregnant or breastfeeding women, or women of childbearing potential who are unwilling to use contraception.",{"count":289,"type":22},300,[291],"NA","Atopic dermatitis (AD) is a skin condition characterized by a rash and itching, resulting from skin inflammation. Ivarmacitinib is an approved medication for treating AD.\n\nThis study assessed the efficacy and safety of switching to the JAK1 inhibitor ivarmacitinib over 16 weeks in patients with moderate-to-severe atopic dermatitis and inadequate response to IL-4Rα inhibitors under real-world conditions.\n\nIt is expected that there will be no additional burden for participants in this trial.",[30],[174,295],"Ivarmacitinib","2026-04-19",{"date":298,"type":45},"2026-04-24",{"date":300,"type":22},"2026-03-31",{"date":302,"type":22},"2027-07-31",{"name":304,"class":52},"Peking University People's Hospital",{"id":306,"slug":307,"hasResults":12,"nctId":308,"briefTitle":309,"officialTitle":310,"acronym":4,"eligibilityCriteria":311,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":312,"targetDuration":64,"studyType":65,"phases":4,"briefSummary":314,"conditions":315,"keywords":319,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":326,"lastUpdatePostDateStruct":327,"startDateStruct":329,"completionDateStruct":331,"leadSponsor":333,"locationsCount":53},"100627417","atopic-dermatitis-treated-with-dupilumab-and-jak-inhibitors-in-costa-rica-100627417","NCT07448363","Atopic Dermatitis Treated With Dupilumab and JAK Inhibitors in Costa Rica","National Registry of Patients With Atopic Dermatitis Under Treatment With Dupilumab and JAK Inhibitors Within the Costa Rican Social Security System","Inclusion Criteria:\n\n* Clinical diagnosis of atopic dermatitis according to accepted diagnostic criteria\n* Moderate-to-severe disease requiring systemic or advanced therapy\n* Receiving systemic immunosuppressive, biologic, or other advanced treatment as part of routine care\n* Evaluated in participating dermatology centers in Costa Rica\n* Available clinical records with baseline and follow-up information\n\nExclusion Criteria:\n\n* Lack of sufficient clinical data for severity or treatment assessment",{"count":313,"type":22},50,"The goal of this observational registry is to characterize the clinical features, severity, treatments, and outcomes of patients with atopic dermatitis in Costa Rica receiving systemic and advanced therapies in routine clinical practice. The main questions it aims to answer are:\n\nWhat are the demographic and clinical characteristics of patients with moderate-to-severe atopic dermatitis treated in specialized dermatology centers in Costa Rica?\n\nWhat treatments are used in real-world practice and how do they impact disease severity and patient-reported outcomes over time?\n\nParticipants with atopic dermatitis receiving systemic or advanced therapies as part of their usual medical care will be followed longitudinally, with collection of clinical severity scores, treatment patterns, and outcomes during routine visits.",[174,30,68,316,317,318],"Atopic Dermatitis Patients","Atopic Dermatitis \u002F Eczema","Atopic Dermatitis, Unspecified",[320,321,322,323,324,246,325],"Registry","Dupilumab","Abrocitinib","Upadacitinib","JAK-inhibitor","Baricitinib","2026-04-02",{"date":328,"type":45},"2026-04-08",{"date":330,"type":22},"2026-05",{"date":332,"type":22},"2031-05",{"name":334,"class":335},"Caja Costarricense de Seguro Social","OTHER_GOV",{"id":337,"slug":338,"hasResults":12,"nctId":339,"briefTitle":340,"officialTitle":341,"acronym":342,"eligibilityCriteria":343,"healthyVolunteers":12,"sex":17,"minAge":344,"maxAge":345,"enrollmentInfo":346,"targetDuration":4,"studyType":23,"phases":348,"briefSummary":350,"conditions":351,"keywords":353,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":358,"lastUpdatePostDateStruct":359,"startDateStruct":361,"completionDateStruct":363,"leadSponsor":365,"locationsCount":4},"100626659","phase-4-efficacy-of-crisaborole-2-cream-versus-placebo-in-mild-to-moderate-atopic-eczema-100626659","NCT07438509","Efficacy of Crisaborole 2% Cream Versus Placebo in Mild to Moderate Atopic Eczema","Evaluation of the Efficacy of Crisaborole 2% Cream Compared to Placebo in the Management of Mild to Moderate Atopic Eczema","CRISA-AD","Inclusion Criteria:\n\n* Age 12 to 50 years\n* Clinically diagnosed mild to moderate atopic dermatitis (ISGA score 2 or 3)\n* Willing and able to apply topical medication twice daily for four weeks\n* Able to provide written informed consent (parental consent for participants under 18 years)\n\nExclusion Criteria:\n\n* Severe atopic dermatitis (ISGA score 4)\n* Use of systemic corticosteroids, immunosuppressants, or antibiotics within the past two weeks\n* Known hypersensitivity to crisaborole or any component of the formulation\n* Pregnant or lactating women\n* Presence of other significant dermatological conditions that may interfere with evaluation (e.g., psoriasis, scabies)\n* Immunocompromised status (e.g., HIV infection, organ transplant recipient)","12 Years","50 Years",{"count":347,"type":22},270,[349],"PHASE4","This randomized controlled trial (RCT) aims to evaluate the efficacy and safety of Crisaborole 2% cream compared with placebo in patients with mild to moderate atopic dermatitis (AD), also known as atopic eczema. AD is a chronic inflammatory skin condition characterized by itching, redness, and recurrent flares that can significantly impair quality of life.\n\nEligible participants aged 12 to 50 years with mild to moderate AD will be randomly assigned to receive either Crisaborole 2% cream or a placebo cream applied twice daily for four weeks. The primary outcome is treatment success at Day 28, defined using the Investigator's Static Global Assessment (ISGA) as a score of 0 (clear) or 1 (almost clear) with at least a two-grade improvement from baseline.\n\nParticipants will be evaluated at baseline, Day 14, and Day 28. Safety, tolerability, and compliance will also be assessed. The results of this RCT may provide locally relevant evidence to guide the management of mild to moderate AD.",[30,352],"Atopic Eczema",[354,355,356,357],"Mild to Moderate Atopic Dermatitis","Crisaborole","Phosphodiesterase-4 Inhibitor","Topical Therapy","2026-03-04",{"date":360,"type":45},"2026-03-06",{"date":362,"type":22},"2026-03-01",{"date":364,"type":22},"2026-09-01",{"name":366,"class":335},"Jinnah Postgraduate Medical Centre",{"id":368,"slug":369,"hasResults":12,"nctId":370,"briefTitle":371,"officialTitle":372,"acronym":4,"eligibilityCriteria":373,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":111,"enrollmentInfo":374,"targetDuration":4,"studyType":23,"phases":376,"briefSummary":378,"conditions":379,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":380,"lastUpdatePostDateStruct":381,"startDateStruct":383,"completionDateStruct":385,"leadSponsor":387,"locationsCount":53},"100622678","phase-3-a-phase-iii-study-of-gs101-injection-to-dupixent-100622678","NCT07386743","A Phase III Study of GS101 Injection to Dupixent®","A Multicenter, Randomized, Double-blinded, Parallel, Positive-controlled, Phase III Comparative Study to Evaluate GS101 Injection Versus Dupixent® in Participants With Moderate-to-Severe Atopic Dermatitis","Inclusion Criteria:\n\n* Subjects, male or female, between the ages of 18 and 75 years (inclusive)\n* At the time of screening, the diagnosis of atopic dermatitis (AD) meets the Hanifin-Rajka criteria, with a disease history for at least 1 year prior to screening\n* During the screening period and at baseline, patients with moderate-to-severe atopic dermatitis, defined as meeting all of the following 3 criteria concurrently: a. IGA score ≥ 3; b. EASI score ≥ 16; c. BSA ≥ 10%.\n\nExclusion Criteria:\n\n* Hypersensitivity or known allergy to the investigational product(s) or any of their excipients\n* Treatment with any investigational drug, medical device, or other biologic agent within 8 weeks prior to randomization or within 5 half-lives (if the half-life is known), whichever is longer\n* Receipt of any live or live-attenuated vaccine within 3 months prior to randomization, or planned receipt of such vaccines during the study period",{"count":375,"type":22},572,[377],"PHASE3","This is a a multicenter, randomized, double-blinded, parallel, positive-controlled, Phase III comparative study to evaluate GS101 Injection versus Dupixent® in participants with moderate-to-severe atopic dermatitis. A total of 572 subjects are planned to be included and randomized at a ratio of 1:1 to receive GS101 injection or Dupixent®",[30],"2026-02-02",{"date":382,"type":45},"2026-02-04",{"date":384,"type":22},"2026-02",{"date":386,"type":22},"2028-01",{"name":231,"class":103},{"id":389,"slug":390,"hasResults":12,"nctId":391,"briefTitle":392,"officialTitle":392,"acronym":4,"eligibilityCriteria":393,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":193,"enrollmentInfo":394,"targetDuration":4,"studyType":23,"phases":396,"briefSummary":397,"conditions":398,"keywords":399,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":401,"lastUpdatePostDateStruct":402,"startDateStruct":404,"completionDateStruct":406,"leadSponsor":408,"locationsCount":4},"100618567","exploratory-clinical-investigation-on-neurosensory-responses-via-eeg-headband-in-adults-with-mild-to-moderate-atopic-dermatitis-after-application-of-marketed-product-compared-with-placebo-water-application-100618567","NCT07333300","Exploratory Clinical Investigation on Neurosensory Responses Via EEG Headband in Adults With Mild to Moderate Atopic Dermatitis After Application of Marketed Product Compared With Placebo (Water Application).","Inclusion Criteria:\n\n* Age: 18 to 65 years (both inclusive) at the time of consent having mild to moderate atopic dermatitis. 2. Sex: Healthy male and non-pregnant\u002Fnon-lactating females. 3. Females of childbearing potential must have a self-reported negative pregnancy test. 4. Subject are generally in good health. 5. Subjects who agree to come to the facility with clean and dry scalp and hair 6. Subjects with mild to moderate Atopic Dermatitis determined by Eczema\n\nArea and Severity Index (EASI) score with moderate erythema (redness:\n\nscore 2) and mild scratch mark (scratching: score 1) will be enrolled into the study 7. Subjects are not allowed to participate in any other study until this study is complete. 8. Subjects willing and able to follow the study directions. 9. Having childbearing potential, is practicing and agrees to maintain an established method of birth control (IUD, hormonal implant device\u002F injection, regular use of birth control pills or patch, diaphragm, condoms with spermicide or sponge with spermicidal jelly, cream or foam,partner vasectomy or abstinence). Females will be considered as nonchildbearing potential if they are surgically sterile, have been postmenopausal for at least 1 year or have had a tubal ligation. 10. Subjects willing to give written consent through subject information sheet. 11. Subjects have not participated in a similar investigation in the past three months. 12. Subjects willing to use test product throughout the study period.\n\nExclusion Criteria:\n\n* History of any dermatological condition of the skin diseases. 2. Subject with present condition of allergic response to any cosmetic product. 3. Subjects with other dermatologic diseases besides AD whose presence or treatments could interfere with the assessment of disease (eg, Psoriasis). 4. Subjects who used systemic immunosuppressants within 4 weeks, topical steroids or immunomodulators within 1 week, moisturizers within 12 hours before evaluation. 5. History of alcohol or drug addiction. 6. The subject has a known allergy or sensitivity to soaps, lotions, detergents, detanglers or fragrances. 7. The subject has any other skin conditions i.e. cuts, scratches, ring worms, etc. which in the opinion of the Investigator, will interfere with the study results or will create undue risk for the subject. 8. Subjects having diabetes, hepatitis, epilepsy, thyroid or have or had any kind of cancer. 9. The subject must not have participated in a clinical study within 4 weeks prior to the screening visit of this study. 10. Any other condition which could warrant exclusion from the study, as per the dermatologist's\u002Finvestigator's discretion. 11. Pregnant or breastfeeding or planning to become pregnant during the study period. 12. History of chronic illness which may influence the cutaneous state.",{"count":395,"type":22},20,[291],"This is a prospective, exploratory, double-blind, single-visit internal validation study designed to evaluate neurosensory responses using electroencephalography head band (EEG) in adult subjects with mild to moderate atopic dermatitis (AD) following a single topical application of marketed product compared with placebo (water application).",[30],[400],"atopic dermatitis","2025-12-30",{"date":403,"type":45},"2026-01-12",{"date":405,"type":22},"2026-01-04",{"date":407,"type":22},"2026-01-06",{"name":409,"class":52},"NovoBliss Research Pvt Ltd",{"id":411,"slug":412,"hasResults":12,"nctId":413,"briefTitle":414,"officialTitle":415,"acronym":416,"eligibilityCriteria":417,"healthyVolunteers":192,"sex":17,"minAge":418,"maxAge":419,"enrollmentInfo":420,"targetDuration":4,"studyType":23,"phases":422,"briefSummary":423,"conditions":424,"keywords":431,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":435,"lastUpdatePostDateStruct":436,"startDateStruct":438,"completionDateStruct":440,"leadSponsor":442,"locationsCount":53},"100617272","birth-cohort-development-of-ige-autoantibodies-in-newborns-with-high-risk-of-atopic-dermatitis-100617272","NCT07316465","Birth Cohort: Development of IgE Autoantibodies in Newborns With (High Risk of) Atopic Dermatitis","Development of IgE Autoantibodies in Newborns With Atopic Dermatitis (DIANA) Birth Cohort","DIANA","Inclusion Criteria:\n\nNewborns who are planned to be born at the maternity ward of UZ Brussel with the following criteria:\n\n* 400 newborns with high-risk for AD-development (at least 1 parent or sibling with physician diagnosed atopic dermatitis AND\u002FOR asthma AND\u002FOR allergic rhinitis)\n* 100 newborns with low-risk for AD-development (no parents or siblings with history of atopic dermatitis AND\u002FOR asthma AND\u002FOR allergic rhinitis)\n\nExclusion Criteria:\n\n* Newborns not born at the maternity ward of UZ Brussel\n* Parents with a poor understanding of Dutch, French or English\n* Newborns who are admitted post-partum to the neonatal intensive care unit (gestational age \\\u003C34 weeks) or with medical complications\n* Newborns with severe genetic abnormalities\u002Fbirth defects\n* Newborns whose parents will not be able to attend the study visits for a period of 2 years (location, working hours)","1 Hour","24 Months",{"count":421,"type":22},500,[291],"Previous research has shown that some patients with atopic eczema have specific self-reactive antibodies, known as IgE autoantibodies, that react to their own skin cells, referred to as \"self-reactive antibodies\" or \"autoantibodies\". It is not yet known when and how these self-reactive antibodies develop, so this is what we aim to investigate.\n\nThis study aims to examine the presence of self-reactive antibodies at birth. In other words, the investigators want to study the earliest stage of developing antibodies that target the body's own skin cells. Additionally, factors that contribute to the development of these self-reactive antibodies will be explored as well as the correlation with the development of atopic eczema.\n\nThe study will involve newborns who are at an increased risk of developing atopic eczema due to a family history of asthma, hay fever, or atopic eczema. There will also be a control group of newborns without these characteristics. The study's approach is to examine a portion of the umbilical cord blood, which is routinely collected after birth, to investigate self-reactive antibodies. The goal is to determine whether these self-reactive antibodies are linked to the development of atopic eczema in the first two years of life. For this purpose, follow-ups will be conducted at the ages of 6, 12, and 24 months.\n\nThis study will contribute to an increased understanding of the prevalence of self-reactive antibodies and the factors influencing their development. Moreover, the study will determine whether these antibodies play a role in the prevention of and\u002For serve as predictive factors for the development of atopic eczema.",[30,425,426,427,428,429,430],"Autoantibody","Auto-Immunity","Microbiome, Human","Allergic Disease","IgE-Mediated Hypersensitivity","Newborn Infant",[432,433,434,246,416],"Birth cohort","Autoantibodies","IgE","2025-12-18",{"date":437,"type":45},"2026-01-05",{"date":439,"type":45},"2023-10-01",{"date":441,"type":22},"2030-12-31",{"name":443,"class":52},"Universitair Ziekenhuis Brussel",{"id":445,"slug":446,"hasResults":12,"nctId":447,"briefTitle":448,"officialTitle":449,"acronym":4,"eligibilityCriteria":450,"healthyVolunteers":192,"sex":17,"minAge":18,"maxAge":193,"enrollmentInfo":451,"targetDuration":4,"studyType":23,"phases":453,"briefSummary":454,"conditions":455,"keywords":456,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":435,"lastUpdatePostDateStruct":457,"startDateStruct":459,"completionDateStruct":461,"leadSponsor":463,"locationsCount":53},"100611038","phase-1-a-phase-11b-study-to-evaluate-safety-tolerability-and-pharmacokinetics-of-zl-1503-in-healthy-volunteers-and-participants-with-moderate-to-severe-atopic-dermatitis-100611038","NCT07235384","A Phase 1\u002F1b Study to Evaluate Safety, Tolerability and Pharmacokinetics of ZL-1503 in Healthy Volunteers and Participants With Moderate to Severe Atopic Dermatitis","A Phase 1\u002F1b Randomized, Double Blind, Placebo-controlled, Single and Multiple Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ZL-1503 in Healthy Volunteers and Participants With Moderate to Severe Atopic Dermatitis (AD)","Inclusion Criteria:\n\n* Part A:\n\n  1. Healthy male and female volunteers, 18-65 years of age\n  2. Body mass index (BMI) between ≥ 18.5 and \\\u003C 32.5 kg\u002Fm2\n  3. Negative pregnancy tests for women of childbearing potential.\n* Part B:\n\n  1. 18-65 years of age;\n  2. BMI between ≥18.5 and \\\u003C40.0 kg\u002Fm2\n  3. Have a diagnosis of AD at least 12 months prior to Day 1;\n  4. Moderate-to-severe AD at Screening and Baseline visit, defined as:\n\n     1. Eczema Area and Severity Index (EASI) score ≥ 16;\n     2. Affected Body Surface Area (BSA)≥ 10%;\n     3. vIGA-AD™ score ≥ 3\n  5. History of an inadequate response to treatment with topical medications\n  6. Average peak pruritus numeric rating scale (PP-NRS) score ≥4 in the 7 days before randomization.\n  7. Negative pregnancy tests for women of childbearing potential.\n\nExclusion Criteria:\n\n* Part A and B:\n\n  1. Significant health issues, such as positive tests for human immunodeficiency virus (HIV), hepatitis C virus (HCV), hepatitis B surface antigen (HBsAg), active tuberculosis, immunodeficiencies or autoimmune diseases.\n  2. History of major metabolic, liver, kidney, hematologic or other significant disorders.\n  3. Abnormal Electrocardiogram (ECG) findings\n  4. Clinically relevant abnormal lab results, including low blood counts, or abnormal liver and kidney function.\n  5. History of drug abuse or addiction within 6 months prior to screening\n  6. Current smoker or use of any nicotine or tobacco containing products within the last 6 months prior to dosing.\n  7. Donated \\>500mL blood within 2 months of dosing.\n* For Part B only:\n\n  1. Presence of dermatologic conditions and\u002For comorbidities that might confound the diagnosis of AD and\u002For might interfere with study assessments.\n  2. Uncontrolled chronic disease that might require bursts of oral corticosteroids.\n  3. Any other sound medical, psychiatric, and\u002For social reason as determined by the investigator.",{"count":452,"type":22},84,[136],"This is a phase 1\u002F1b randomized, double blind, placebo-controlled, single dose escalation (SAD) and multiple dose escalation (MAD) study to evaluate the safety, tolerability, and pharmacokinetics (PK) of ZL-1503 in healthy volunteers and participants with moderate to severe atopic dermatitis (AD)",[30],[174],{"date":458,"type":45},"2025-12-19",{"date":460,"type":45},"2025-12-01",{"date":462,"type":22},"2027-12-28",{"name":464,"class":103},"Zai Lab (Shanghai) Co., Ltd.",{"id":466,"slug":467,"hasResults":12,"nctId":468,"briefTitle":469,"officialTitle":470,"acronym":4,"eligibilityCriteria":471,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":472,"targetDuration":4,"studyType":23,"phases":474,"briefSummary":475,"conditions":476,"keywords":477,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":435,"lastUpdatePostDateStruct":481,"startDateStruct":482,"completionDateStruct":484,"leadSponsor":486,"locationsCount":488},"100591586","phase-1-safety-and-pharmacokinetics-of-lpx-ti641-in-atopic-dermatitis-and-psoriasis-100591586","NCT06982352","Safety and Pharmacokinetics of LPX-TI641 in Atopic Dermatitis and Psoriasis","Phase 1b Randomized, Double Blind, Placebo-controlled Study to Evaluate Safety, Tolerability and Pharmacokinetics of LPX-TI641 in Patients With Atopic Dermatitis and Psoriasis","Inclusion Criteria:\n\n1. Subject has signed an Informed Consent Form (ICF) prior to any study-specific procedures being performed\n2. ≥ 18 years old, irrespective of their race and ethnicity.\n3. Body Mass Index (BMI) 18.0-40.0 kg\u002Fm2, inclusive, at screening.\n4. Participants are willing and able to adhere to study protocol requirements and restrictions including but not limited to scheduled outpatient visits, inpatient stay, laboratory tests, and 12-lead ECGs.\n5. The subject must be judged to be in good health by the investigator to participate in the study, based on clinical evaluations, including laboratory safety tests, medical history, physical examination, vital signs and 12-lead ECG completed at the screening visit and prior to the first dose of study drug.\n6. Female subject is postmenopausal (at least 1 year; to be confirmed by FSH if less than 2 years since last menstrual period), permanently sterilized (e.g. tubal occlusion, hysterectomy, bilateral salpingectomy) or if of childbearing potential and engaged in sexual activity that can result in pregnancy must agree to use any two of the highly effective contraception methods listed below. Male participants with a partner of childbearing potential must also agree to use any two of the highly effective contraception methods listed below between them and their partner. This criterion must be followed from screening visit to 6 weeks after the last dose in females and for 90 days after the last dose for males.\n\n   The following applies to all female participants with childbearing potential and female partners of male participants enrolled in the study.\n   1. Implantable progestogen-only hormone contraception associated with inhibition of ovulation.\n   2. Intrauterine device.\n   3. Intrauterine hormone-releasing system.\n   4. Bilateral tubal occlusion.\n   5. Combined (estrogen- and progestogen-containing) hormonal contraception associated with inhibition of ovulation:\n   6. Oral\n   7. Intravaginal\n   8. Transdermal\n   9. Injectable\n   10. Progestogen-only hormone contraception (oral or injectable) associated with inhibition of ovulation.\n   11. Vasectomized partner\n   12. Sexual abstinence -this is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study intervention. The reliability of sexual abstinence needs to be evaluated about the duration of the study and the preferred and usual lifestyle of the participant.\n   13. A combination of male condoms with either cervical cap, diaphragm, or sponge with spermicide (double-barrier methods)\n\n       The following applies to all male participants in the study:\n   14. Sexual abstinence- this is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study intervention. The reliability of sexual abstinence must be evaluated for the study and the participant's preferred and usual lifestyle.\n   15. A combination of male condoms with either cervical cap, diaphragm, or sponge with spermicide (double-barrier methods).\n   16. Vasectomy\n7. Negative serum B-human chorionic gonadotropin test at screening (for all females) and negative urine pregnancy at randomization (Day 1) (females of childbearing potential) prior to administration of investigational product.\n\n   For Atopic Dermatitis Cohort:\n8. Diagnosis of AD at least 12 months prior to screening, as defined by the American Academy of Dermatology: Guidelines of care for the management of atopic dermatitis (Eichenfield 2014):\n\n   1. EASI score ≥ 16 at Screening and baseline (Day 0)\n   2. vIGA score of ≥3 at screening and baseline (Day 0)\n   3. ≥10% of body surface area (BSA) involvement at screening and baseline (Day 0)\n   4. Peak pruritis NRS≥4 (average score of daily scores 7 days before Day 0)\n9. History, documented by a physician and\u002For investigator, of inadequate response to existing topical medications within 6 months preceding screening, or history of intolerance to topical therapy as defined by at least 1 of the following:\n\n   1. Inability to achieve good disease control defined as mild disease or better (e.g., IGA≤2) after use of at least a medium potency topical corticosteroid (TCS) for at least 4 weeks, or for the maximum duration recommended by the product prescribing information (e.g. 14 days for super potent TCS), whichever is shorter (Note: a TCS may be used with or without topical calcineurin inhibitors \\[TCNIs\\])\n   2. Documented history of clinically significant adverse reactions with the use of TCS, such as skin atrophy, allergic reactions, or systemic effects that, in the opinion of the investigator, outweigh the benefits of retreatment\n   3. Failed systemic therapies intended to treat AD within 6 months preceding screening (will be considered as having inadequate response to topical therapy)\n10. Documented history of clinically significant adverse reactions with the use of TCS, such as skin atrophy, allergic reactions, or systemic effects that, in the opinion of the investigator, outweigh the benefits of retreatment\n\n    For Plaque Psoriasis Cohort:\n11. Confirmed diagnosis of plaque psoriasis for at least 6 months prior to baseline (Day 0)\n12. Plaque psoriasis involving ≥10% body surface area (BSA) in the affected skin other than the face and scalp at screening and baseline (Day 0)\n13. Static Physician's Global Assessment (sPGA) score ≥3 at screening and baseline (Day 0)\n14. PASI score of ≥12 at screening and baseline (Day 0)\n15. Subject must be candidate for phototherapy or systemic therapy\n16. Subject had no significant flare in psoriasis for at least 3 months before screening\n\nExclusion Criteria:\n\n1. History of clinically significant medical conditions or any other reason that in the opinion of the PI would interfere with subject's participation in this study\n2. History of clinically significant drug or alcohol abuse per the PI's opinion within the last 6 months.\n3. Pregnant or lactating women or women currently undergoing infertility treatments or women who intend to become pregnant during the time of study or for 6 weeks after last dose.\n4. Presence of skin comorbidities that would interfere with study assessment or response to treatment\n5. Any known history of malignancy within 5 years other than completely treated non-metastatic basal cell carcinomas or squamous cell carcinomas of the skin or localized carcinoma in situ of the cervix.\n6. Patients who are currently experiencing a skin infection that requires treatment, or is currently being treated, with topical or systemic antibiotics\n7. Symptomatic herpes zoster within 3 months of screening\n8. For the plaque psoriasis cohort,\n\n   1. Unstable forms of PsO (acute guttate PsO, psoriatic erythroderma, generalized pustular PsO, or other unstable form as judged by the investigator), or drug-induced psoriasis.\n   2. History of any non-PsO disease that required treatment with oral or parenteral corticosteroids for more than 2 weeks within the past 24 weeks prior to signing the informed consent form (ICF)\n9. Receipt of an investigational therapy less than 3 months or 5 drug-elimination half-lives (whichever is longer) prior to first administration of study treatment and during the study\n10. Use of the following topical medications\u002Femollients which could affect assessment of disease activity for at least 2 weeks prior to baseline (Day 0) and throughout the study:\n\n    1. Topical corticosteroids or topical immune modulators (e.g. tacrolimus or pimecrolimus)\n    2. Topical phosphodiesterase type 4 (PDE 4) inhibitor or JAK inhibitors or aryl hydrocarbon receptor agonists\n    3. Topical or systemic antihistamines\n    4. Use of emollients.\n11. Receipt of any of the following excluded therapies as per below and throughout the study:\n\n    1. Oral retinoids within 2 weeks of Day 0\n    2. Systemic immunosuppressive\u002Fimmunomodulating therapy (such as but not limited to systemic glucocorticoids, cyclosporine, mycophenolate mofetil, methotrexate, azathioprine, apremilast, or oral JAK inhibiting agents or phototherapy within 4 weeks before screening visit. Stable dose of max 1200ug inhaled budesonide (or equivalent) is allowed.\n    3. Any cell depleting therapy, anti-CD4, anti-CD5, anti-CD3 other than anti-CD20 such as rituximab, ocrelizumab, and ofatumumab. Patients who have received rituximab or other selective B lymphocyte depleting agents (including experimental agents) are eligible if they have not received such therapy for at least 1 year prior to screening\n12. Biologics dugs including, but not limited to dupilumab, tralokinumab, ustekinumab, secukinumab, ixikizumab, anti-TNF inhibitors within 8 weeks or 5 drug elimination half-lives whichever is longer and throughout the study\n13. Failed biologics due to efficacy including, but not limited to dupilumab, tralokinumab, ustekinumab, secukinumab, ixikizumab, anti-TNF inhibitors\n14. PUVA or UVB phototherapy within 4 weeks prior to Day 0 and throughout the study.\n15. Subject has clinical or laboratory evidence of active or latent tuberculosis (TB) infection at screening as assessed by QuantiFERON-TB-Gold or a purified protein derivative skin test or equivalent (or both if required per local guidelines) and chest X-ray. Chest X-rays taken within 2 months prior to screening may be used instead of during screening if there is documentation showing no evidence of infection or malignancy as read by qualified physician.\n16. Any active or recurrent infection within 1) the past 8 weeks prior to screening requiring IV\u002Fhospitalization or 2) the past 2 weeks prior to screening requiring oral antibiotics.\n17. Laboratory values of the following at the Screening Visit:\n\n    1. Hemoglobin \\\u003C 11 g\u002FdL\n    2. WBC \\\u003C3.5X109\u002FL\n    3. Absolute neutrophil count (ANC) \\\u003C 1500 cells\u002FµL, (or \\\u003C 1200 cells\u002FµL for participants of African descent who are black)\n    4. Aspartate aminotransferase or alanine aminotransferase \\> 2.0 x the upper limit of normal (ULN) or bilirubin \\>= ULN;\n    5. Bilirubin \\> ULN\n    6. Platelets \\\u003C 100,000 cells\u002F\\[mm\\^3\\] (10\\^9\u002FL)\n    7. Clinically significant abnormal screening laboratory results as evaluated by the Investigator\n18. Acutely worsened renal function within past 3 months prior to screening or estimated GFR by CDK-EPI creatinine equation with adjustment for body surface area \\\u003C60ml\u002Fmin.\n19. Subject has any clinically significant finding on 12-lead ECG at screening or admission. NOTE: QTc(F) interval of \\>450 msec in male participants or \\>470 msec in female participants will be the basis for exclusion from the study. ECG may be repeated once for confirmatory purposes if initial values obtained exceed the limits specified.\n20. Subject with positive results for HBsAg (hepatitis B surface antigens) and\u002For HBcAb (Hepatitis B core antibodies) and\u002For HCV Ab (hepatitis C antibodies) confirmed by HCV RNA, and\u002For HIV Ab (human immunodeficiency virus antibodies).\n21. Blood loss of \\>250 mL or donated blood within 56 days or donated plasma within 7 days of screening.\n22. Recent vaccination with live attenuated vaccines such as influenza, MMR, Herpes zoster, varicella, yellow fever, Rotavirus vaccine, etc., or inactivated vaccines such as Hepatitis A, rabies vaccine, etc. 30 days prior to screening visit\n23. Subject has known sensitivity to any of the components of the investigational product.\n24. Subject is investigative site personnel, sponsor personnel, or a member of their immediate families (spouse, parent, child or sibling whether biological or legally adopted).",{"count":473,"type":22},48,[136],"The goal of this clinical trial is to study the drug LPX-TI641 in patients with atopic dermatitis and psoriasis. We will compare the safety and tolerability of LPX-TI641 to placebo ( a look-alike solution) that contains no drug. We will also evaluate the plasma pharmacokinetics of LPX-TI641. LPX-TI641 (or placebo) will be administered orally for 28 days.",[30,142],[478,479,480],"phase 1 study","safety","pharmacokinetics",{"date":458,"type":45},{"date":483,"type":45},"2025-06-15",{"date":485,"type":22},"2026-04-15",{"name":487,"class":103},"LAPIX Therapeutics Inc.",3,{"id":490,"slug":491,"hasResults":12,"nctId":492,"briefTitle":493,"officialTitle":494,"acronym":495,"eligibilityCriteria":496,"healthyVolunteers":192,"sex":17,"minAge":497,"maxAge":498,"enrollmentInfo":499,"targetDuration":4,"studyType":23,"phases":501,"briefSummary":502,"conditions":503,"keywords":4,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":504,"lastUpdatePostDateStruct":505,"startDateStruct":507,"completionDateStruct":509,"leadSponsor":511,"locationsCount":125},"100588597","effect-of-partially-hydrolyzed-formula-with-synbiotics-on-skin-barrier-function-100588597","NCT06943469","Effect of Partially Hydrolyzed Formula With Synbiotics on Skin Barrier Function","Synbiotics in Partially Hydrolysed Formula for Improved skiN Barrier Function in Infants at Risk for Allergy (SPHINX Study)","SPHINX","Inclusion Criteria:\n\n1. Written informed consent has been obtained from at least one parent or legally acceptable representative (LAR), if applicable\n2. Infant gestational age ≥ 37 completed weeks\n3. Infant birth weight of ≥ 2.5 kg and ≤ 4.5 kg\n4. Infant postnatal age ≤ 14 days (date of birth = day 0) at enrollment\n5. Infant from singleton birth or infant from multiple births may if all birth siblings are enrolled.\n6. At least one biological parent or sibling has (or had) a medically diagnosed history of allergy, based on response to a simple screening questionnaire\n7. a. For the breastfed reference group only: infant is exclusively breastfed since birth with no intake of formula, and their parent(s) have the intention to continue exclusive breastfeeding until at least 4 months of age.\n\n   or b. For the randomized formula-fed groups only: infant is exclusively or predominantly formula-fed in the 24 hours prior to enrollment, with formula feeding representing at least 75% of total daily feeds. The decision to introduce formula feeding was independently made by the parents before enrollment.\n8. Parents\u002FLAR must be able to provide evidence of parental authority and identity.\n9. Infant's parent(s)\u002FLAR must understand the informed consent form and other study documents and are willing and able to fulfill the requirements of the study protocol.\n\nExclusion Criteria:\n\n1. Infectious, metabolic, congenital, genetic, gastrointestinal illness or any other condition (e.g., gastrointestinal surgery) that could impact oral feeding, growth or study outcomes.\n2. Infants with special dietary needs other than standard infant formula (e.g., extensively hydrolyzed formula, amino acid formula, special formula for metabolic diseases) or requiring tube feeding.\n3. Infant has already been diagnosed with allergy by a physician, including AD and\u002For cow's milk allergy.\n4. Infant is currently participating or has previously participated in another clinical trial prior to enrollment.\n5. Infant's parents or LARs have not reached legal age of majority (18 years).","1 Day","14 Days",{"count":500,"type":22},400,[291],"The main purpose of this study is to assess the efficacy of a partially hydrolyzed formula with synbiotics in halting one of the first steps of the allergic march (atopic dermatitis) in infants at risk of allergy. Other efficacy and safety parameters will be assessed as well.",[30],"2025-12-11",{"date":506,"type":45},"2025-12-12",{"date":508,"type":45},"2025-04-10",{"date":510,"type":22},"2028-11",{"name":512,"class":103},"Société des Produits Nestlé (SPN)",{"id":514,"slug":515,"hasResults":12,"nctId":516,"briefTitle":517,"officialTitle":518,"acronym":4,"eligibilityCriteria":519,"healthyVolunteers":12,"sex":17,"minAge":344,"maxAge":111,"enrollmentInfo":520,"targetDuration":4,"studyType":23,"phases":521,"briefSummary":522,"conditions":523,"keywords":524,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":525,"lastUpdatePostDateStruct":526,"startDateStruct":527,"completionDateStruct":529,"leadSponsor":531,"locationsCount":4},"100614209","treatment-of-moderate-to-severe-atopic-dermatitis-with-ivarmacitinib-in-adolescents-and-adults-100614209","NCT07276620","Treatment of Moderate-to-Severe Atopic Dermatitis With Ivarmacitinib in Adolescents and Adults","A Study on the Efficacy and Safety of Ivarmacitinib in the Treatment of Moderate to Severe Atopic Dermatitis in Adolescents and Adults","Inclusion Criteria:\n\n* Aged between 12 and 75 years;\n* Diagnosed with moderate-to-severe atopic dermatitis (AD) ;\n* Participants (and legal representatives for adolescents) able to understand and communicate with the investigator.\n\nExclusion Criteria:\n\n* Subject has any of the following abnormalities in clinical laboratory tests at screening, as assessed by the study-specific laboratory and confirmed by a single repeat, if deemed necessary:\n\n  1. Absolute lymphocyte count of \\\u003C0.50 x 10\\^9 \u002FL (\\\u003C500\u002Fmm3);\n  2. Absolute Neutrophil Count (ANC) of \\\u003C1 X 10\\^9\u002FL (\\\u003C1000\u002Fmm3);\n  3. Hemoglobin level \\\u003C 80 g\u002FL.\n* Subject has any malignancies or has a history of malignancies with the exception of adequately treated or excised non-metastatic basal cell or squamous cell cancer of the skin, or cervical carcinoma in situ.\n* Subject with a prior history of thromboembolic events, including deep vein thromboses (DVT), pulmonary embolism, cerebrovascular accidents and those with known inherited conditions that predispose to hypercoagulability.\n* Presence of an active severe acute or chronic bacterial, fungal, or viral infection requiring systemic therapy.\n* Subjects with active tuberculosis or known active hepatitis B and\u002For hepatitis C infection.\n* Subjects with clinically significant diseases of the heart, liver, kidney, or other major organ systems.\n* Female subject who is pregnant, breastfeeding, or considering pregnancy during the study.",{"count":90,"type":22},[291],"Atopic dermatitis (AD) is a skin condition characterized by a rash and itching, resulting from skin inflammation. Ivarmacitinib is an approved medication for treating AD.\n\nThis study aims to evaluate the effectiveness and safety of Ivarmacitinib in the treatment of moderate-to-severe atopic dermatitis under real-world conditions. It will assess the time to pruritus improvement and skin lesion clearance, collect large-sample safety data, analyze disease improvement across patient subgroups with different baseline characteristics, and explore the impact of various maintenance treatment regimens on disease recurrence.\n\nIt is expected that there will be no additional burden for participants in this trial.",[30],[174,295],"2025-12-10",{"date":504,"type":45},{"date":528,"type":22},"2025-11-30",{"date":530,"type":22},"2029-01-30",{"name":532,"class":52},"Xiangya Hospital of Central South University",{"id":534,"slug":535,"hasResults":12,"nctId":536,"briefTitle":537,"officialTitle":538,"acronym":4,"eligibilityCriteria":539,"healthyVolunteers":12,"sex":17,"minAge":344,"maxAge":18,"enrollmentInfo":540,"targetDuration":4,"studyType":23,"phases":542,"briefSummary":543,"conditions":544,"keywords":545,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":549,"lastUpdatePostDateStruct":550,"startDateStruct":552,"completionDateStruct":554,"leadSponsor":555,"locationsCount":53},"100613774","moisturization-and-skin-hydration-study-100613774","NCT07270965","Moisturization and Skin Hydration Study","Understanding the Effect of Pre-Drying Moisturization on Skin Hydration","Inclusion Criteria:\n\n* Participants must have a diagnosis of atopic dermatitis\u002Feczema.\n* Participants must be between the age of 12-18.\n* Participants must be able to bathe independently.\n* Participants will be English speaking and able to complete questionnaires.\n\nExclusion Criteria:\n\n* Participants who use topical corticosteroids between one inch above the wrist and 1 inch below the elbow from 1 month on both arms prior to the study until the final visit.\n* Participants who have a known allergy to the moisturizer cream (Cerave Moisturizing Cream) provided.",{"count":541,"type":22},30,[291],"Skin moisturization is important for patients with atopic dermatitis, commonly known as eczema. Moisturizing right after bathing is widely accepted as the best method to keep skin hydrated. However, there is conflicting research on the timing of moisturizing. The goal of this clinical study is to evaluate the preference of moisturizing while showering\u002Fbathing compared to after towel drying in adolescents aged 12-18 with eczema. The main question it aims to answer are:\n\n* Which moisturization technique is preferred: while showering\u002Fbathing or after towel drying?\n* How do these techniques affect investigator-assessed eczema severity, patient-reported itch scores, and objective skin hydration measurements?\n\nResearchers will compare applying moisturizer while in the shower\u002Fbath to after towel drying and to which technique is preferred among participants and if there are different effects on eczema and skin hydration.\n\nParticipants will:\n\n* Apply moisturizer while showering\u002Fbathing for one month and after towel drying for one month.\n* Complete questionnaires on moisturization technique, skin feel, and itchiness.\n* Undergo skin hydration measurements using a Corneometer® CM825 device.",[30,68],[174,175,238,546,547,548],"Moisturizer","Cream","Skin Hydration","2025-12-03",{"date":551,"type":45},"2025-12-08",{"date":553,"type":22},"2025-12",{"date":122,"type":22},{"name":556,"class":52},"University of British Columbia",{"id":558,"slug":559,"hasResults":12,"nctId":560,"briefTitle":561,"officialTitle":562,"acronym":563,"eligibilityCriteria":564,"healthyVolunteers":12,"sex":17,"minAge":565,"maxAge":344,"enrollmentInfo":566,"targetDuration":4,"studyType":23,"phases":567,"briefSummary":568,"conditions":569,"keywords":570,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":575,"lastUpdatePostDateStruct":576,"startDateStruct":578,"completionDateStruct":580,"leadSponsor":582,"locationsCount":53},"100612881","effect-of-an-emollient-cream-containing-a-milk-bioactive-peptide-on-clinical-signs-pruritus-and-bacterial-colonization-of-mild-atopic-dermatitis-skin-lesions-in-pediatric-population-100612881","NCT07259343","Effect of an Emollient Cream Containing a Milk Bioactive Peptide on Clinical Signs, Pruritus and Bacterial Colonization of Mild Atopic Dermatitis Skin Lesions in Pediatric Population","Effect of Glycomacropeptide on Clinical Manifestations of Atopic Dermatitis in Children: a Pilot Study","AD-GMP-SCORAD","Inclusion Criteria:\n\n* Children aged between 2 and 12 years.\n* Clinical diagnosis of atopic dermatitis according to Hanifin and Rajka criteria.\n* Mild atopic dermatitis with SCORAD \\\u003C25 points.\n* Written informed consent signed by parents or legal guardian.\n\nExclusion Criteria:\n\n* Age younger than 2 years or older than 12 years.\n* Moderate to severe atopic dermatitis (SCORAD \\>25 points).\n* Presence of other dermatoses in addition to atopic dermatitis.\n* Background of hypersensitivity or anaphylaxis to any components of the vehicle cream.\n* Allergy or hypersensitivity to glycomacropeptide.\n* Inability to attend follow-up medical consultations or to adhere to the treatment schedule.\n* Any clinical reason determined by the clinical investigator that makes the child unsuitable for the study.","2 Years",{"count":395,"type":22},[291],"The goal of this clinical trial is to evaluate the protective effect of glycomacropeptide on the clinical signs and symptoms of atopic dermatitis in children aged 2 to 12 years, and to determine if topical administration of glycomacropeptide is associated with a lower colonization by Staphylococcus species on the skin. The main questions that it aims to answer are:\n\n* Does glycomacropeptide reduce the signs and symptoms related to atopic dermatitis in the pediatric population?\n* Does glycomacropeptide modify the colonization of Staphylococcus species in atopic dermatitis lesions in the pediatric population? Researchers will compare an emollient cream containing glycomacropeptide with an emollient cream without glycomacropeptide to evaluate whether treatment with glycomacropeptide achieves a greater reduction in the clinical severity and pruritus of atopic dermatitis and a lower bacterial colonization compared with the exclusive use of emollients.\n\nParticipants will:\n\n* Read and sign the informed consent\n* Undergo a prick test at the first visit to ensure no reaction to the treatment components\n* Receive the assigned treatment (glycomacropeptide cream or emollient cream), which must be applied twice daily only to atopic dermatitis lesions.\n* Visit the clinic once a week for 4 weeks for follow-up and SCORAD assessments, and for skin sample collection by stripping at first and last visit.",[30],[571,572,573,574],"glycomacropeptide","eczema","priritus","Staphylococcus","2025-11-26",{"date":577,"type":45},"2025-12-02",{"date":579,"type":45},"2025-09-26",{"date":581,"type":22},"2026-12-31",{"name":583,"class":52},"Universidad Autónoma de Aguascalientes",{"id":585,"slug":586,"hasResults":12,"nctId":587,"briefTitle":588,"officialTitle":589,"acronym":4,"eligibilityCriteria":590,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":591,"targetDuration":4,"studyType":23,"phases":593,"briefSummary":594,"conditions":595,"keywords":4,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":596,"lastUpdatePostDateStruct":597,"startDateStruct":599,"completionDateStruct":600,"leadSponsor":602,"locationsCount":53},"100610661","phase-2-a-long-term-safety-and-efficacy-study-evaluating-cm512-in-atopic-dermatitis-100610661","NCT07230483","A Long-term Safety and Efficacy Study Evaluating CM512 in Atopic Dermatitis.","An Open-Label, Multicenter Study to Evaluate Long-Term Safety and Efficacy of CM512 in Atopic Dermatitis Patients.","Inclusion Criteria:\n\n* Have the ability to understand the study and voluntarily sign a written informed consent form (ICF).\n* Subjects who have completed the week 18 evaluation in the parent study CM512-101102 or the End of Study(EOS) visit in the parent study CM512-100001.\n\nExclusion Criteria:\n\n* Not enough washing-out period for previous therapy.\n* Any other condition assessed by the investigator that makes participants unsuitable for participation in this study.",{"count":592,"type":22},246,[25],"This is an Open-label ,Multicenter Study to evaluate Long-Term Safety and Efficacy of CM512 in patients with Atopic Dermatitis who have completed treatment in parent CM512 Study.",[30],"2025-11-13",{"date":598,"type":45},"2025-11-17",{"date":553,"type":22},{"date":601,"type":22},"2027-12",{"name":603,"class":103},"Keymed Biosciences Co.Ltd",{"id":605,"slug":606,"hasResults":12,"nctId":607,"briefTitle":608,"officialTitle":609,"acronym":610,"eligibilityCriteria":611,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":612,"enrollmentInfo":613,"targetDuration":4,"studyType":23,"phases":615,"briefSummary":616,"conditions":617,"keywords":4,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":618,"lastUpdatePostDateStruct":619,"startDateStruct":621,"completionDateStruct":623,"leadSponsor":625,"locationsCount":53},"100608669","cerave-effect-on-restoring-skin-hydration-as-maintenance-regimen-in-subjects-with-mild-to-moderate-atopic-dermatitis-100608669","NCT07204561","CeraVe Effect on Restoring Skin Hydration as Maintenance Regimen in Subjects With Mild to Moderate Atopic Dermatitis","Analysis of the CeraVe Emollient Effect on Restoring the Hydration of the Skin Barrier as Maintenance Regimen in Subjects With Mild to Moderate Atopic Dermatitis","DA_CeraVe","Inclusion criteria:\n\nSubjects with clinically confirmed mild-to-moderate atopic dermatitis (AD), as defined by an Eczema Area and Severity Index (EASI) score of 1-21, whose lesions will clear after treatment with a steroid and who will experience at least a 90% reduction in their EASI score.\n\n\\- Participants of any gender, aged 18 years or over, from any phototype or ethnic group.\n\nParticipants must be willing and able to give informed consent to participate in the study.\n\nExclusion criteria:\n\n* Age \\\u003C18 years. Participants who are unwilling or unable to give informed consent to participate in the study.\n* Receiving any systemic treatment for atopic dermatitis (AD), including corticosteroids, cyclosporine, any approved biologics or JAK inhibitors.\n* Any dermatological disorder which, in the investigator's opinion, may interfere with the accurate evaluation of the subject's skin characteristics (except AD).","99 Years",{"count":614,"type":22},98,[291],"This is an open-label, randomised, comparative, prospective, interventional study of a cosmetic product.",[30],"2025-09-24",{"date":620,"type":45},"2025-10-02",{"date":622,"type":45},"2025-03-25",{"date":624,"type":22},"2026-07",{"name":626,"class":52},"Societa Italiana di Dermatologia Medica, Chirurgica, Estetica e di Malattie Sessualmente Trasmesse",{"id":628,"slug":629,"hasResults":12,"nctId":630,"briefTitle":631,"officialTitle":632,"acronym":4,"eligibilityCriteria":633,"healthyVolunteers":12,"sex":17,"minAge":634,"maxAge":61,"enrollmentInfo":635,"targetDuration":4,"studyType":23,"phases":637,"briefSummary":638,"conditions":639,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":640,"lastUpdatePostDateStruct":641,"startDateStruct":643,"completionDateStruct":645,"leadSponsor":647,"locationsCount":53},"100607137","phase-3-a-phase-3-trial-of-opa-15406-foam-in-children-and-infants-with-atopic-dermatitis-100607137","NCT07184645","A Phase 3 Trial of OPA-15406 Foam in Children and Infants With Atopic Dermatitis","A Multicenter, Randomized, Double-blind, Vehicle-controlled, Parallel-group Comparison Trial to Demonstrate the Superiority of 0.3% OPA-15406 Foam to the Vehicle in Children With Atopic Dermatitis in Combination With an Open-label, Uncontrolled Trial to Evaluate the Safety and Efficacy of 0.3% and 1% OPA-15406 Foam in Infants Under 2 Years of Age and Children With Atopic Dermatitis (Phase 3 Trial)","Inclusion Criteria:\n\n* Participants who have been diagnosed with AD based on the Diagnostic Criteria for Atopic Dermatitis (Criteria of the Japanese Dermatological Association)\n* Participants who have an affected area covering from 5% to 40% of their body surface area (excluding the scalp) at the screening and baseline examinations\n* Participants with an IGA score of 2 or 3 at the screening and baseline examinations\n\nExclusion Criteria:\n\n* Participants who experienced an acute exacerbation of AD or contact dermatitis within 28 days prior to the baseline examination\n* Participants who have been treated with OPA-15406 ointment in the past","3 Months",{"count":636,"type":22},198,[377],"To investigate the superiority of 0.3% OPA-15406 foam to the vehicle in children with atopic dermatitis (AD)",[30],"2025-09-18",{"date":642,"type":45},"2025-09-22",{"date":644,"type":22},"2025-09",{"date":646,"type":22},"2027-02",{"name":648,"class":103},"Otsuka Pharmaceutical Co., Ltd."]